Aligos Therapeutics (ALGS) Accumulated Depreciation & Amortization (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $12.7 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 7.89% year-over-year to $12.7 million, compared with a TTM value of $12.7 million through Dec 2025, up 7.89%, and an annual FY2025 reading of $12.7 million, up 7.89% over the prior year.
- Accumulated Depreciation & Amortization was $12.7 million for Q4 2025 at Aligos Therapeutics, up from $12.2 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $12.7 million in Q4 2025 and bottomed at $5.0 million in Q1 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $9.2 million, with a median of $9.3 million recorded in 2022.
- The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 59.25% in 2022, then rose 7.89% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $7.3 million in 2021, then skyrocketed by 31.75% to $9.6 million in 2022, then increased by 12.41% to $10.8 million in 2023, then grew by 9.55% to $11.8 million in 2024, then grew by 7.89% to $12.7 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for ALGS at $12.7 million in Q4 2025, $12.2 million in Q2 2025, and $11.8 million in Q4 2024.